Zhu CL, Peng LZ. Clinical analysis of multiple primary gastrointestinal malignant tumors: A 10-year case review of a single-center. World J Gastrointest Oncol 2024; 16(4): 1204-1212 [PMID: 38660651 DOI: 10.4251/wjgo.v16.i4.1204]
Corresponding Author of This Article
Ling-Zhi Peng, MD, Chief Doctor, Department of Surgical Oncology, Gansu Provincial Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. plz198996@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1204-1212 Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1204
Clinical analysis of multiple primary gastrointestinal malignant tumors: A 10-year case review of a single-center
Cheng-Lou Zhu, Ling-Zhi Peng
Cheng-Lou Zhu, Ling-Zhi Peng, The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, Gansu Province, China
Cheng-Lou Zhu, Ling-Zhi Peng, Department of Surgical Oncology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Author contributions: Zhu CL and Peng LZ made significant contributions to the conceptualization and the design of this study; Zhu CL and Peng LZ collected all the data; Zhu CL and Peng LZ were the main contributors to this manuscript; Zhu CL and Peng LZ made significant revisions to this manuscript; All authors contributed to the article and approved the submitted version.
Supported bythe Natural Science Foundation of Gansu Province, No. 23JRRA1317, and No. 22JR11RA252.
Institutional review board statement: Our study was approved by The Medical Ethics Committee of Gansu Provincial Hospital, No. 2022-191.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data generated or analysed during this study are included in this article. Further enquiries can be directed to the corresponding author at plz198996@163.com.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ling-Zhi Peng, MD, Chief Doctor, Department of Surgical Oncology, Gansu Provincial Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. plz198996@163.com
Received: January 13, 2024 Peer-review started: January 13, 2024 First decision: January 30, 2024 Revised: February 2, 2024 Accepted: March 6, 2024 Article in press: March 6, 2024 Published online: April 15, 2024 Processing time: 88 Days and 10.1 Hours
ARTICLE HIGHLIGHTS
Research background
A literature review of 1104269 patients with cancer revealed that the incidence of multiple primary malignant tumors (MPMTs) ranged from 0.73% to 11.7%. In recent years, however, there has been a significant upward trend in the incidence of this phenomenon.
Research motivation
The overarching motivation of this investigation was to thereby determine whether the gastrointestinal tract is particularly susceptible to second or third primary cancers, and to aid in the early diagnosis of these lesions by clarifying any such tendency.
Research objectives
The aim of this study was to analyze the incidence, clinical features, treatment factors, prevalence, and prognosis of patients with MPMTs in the gastrointestinal tract treated in a single center.
Research methods
The study analyzed 8059 patients with pathologically confirmed gastrointestinal malignant tumors between June 2011 and June 2020. Of these, 85 patients had MPMTs. The clinical features, treatment factors, prevalence, and prognosis of this latter cohort were analyzed.
Research results
The incidence of MPMTs in patients with gastrointestinal malignant tumors was 1.05%, including 83 double primary malignant tumors and two triple primary malignant tumors of which 67.06% were synchronous MPMTs (SMPMTs) and 32.94% were metachronous MPMTs (MMPMTs). The most frequent associations were found between the rectum colon cancers within the SMPMT category and the gastric-colon cancers within the MMPMT category.
Research conclusions
MPMTs in the gastrointestinal tract have a high incidence and poor prognosis.
Research perspectives
It is necessary to perform both gastroscopy and colonoscopy in patients with gastrointestinal tumors. Multidisciplinary comprehensive diagnosis and treatment may improve the diagnosis rate and treatment efficiency of MPMTs.
